89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.
about
89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast CancerEvaluation of antibody fragment properties for near-infrared fluorescence imaging of HER3-positive cancer xenografts
P2860
89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
89Zr-Lumretuzumab PET Imaging ...... in Patients with Solid Tumors.
@en
89Zr-Lumretuzumab PET Imaging ...... in Patients with Solid Tumors.
@nl
type
label
89Zr-Lumretuzumab PET Imaging ...... in Patients with Solid Tumors.
@en
89Zr-Lumretuzumab PET Imaging ...... in Patients with Solid Tumors.
@nl
prefLabel
89Zr-Lumretuzumab PET Imaging ...... in Patients with Solid Tumors.
@en
89Zr-Lumretuzumab PET Imaging ...... in Patients with Solid Tumors.
@nl
P2093
P2860
P1476
89Zr-Lumretuzumab PET Imaging ...... in Patients with Solid Tumors
@en
P2093
Adrienne H Brouwers
Annelies Jorritsma-Smit
Anton G T Terwisscha van Scheltinga
Carolien P Schröder
Celine Adessi
Frederike Bensch
Georgina Meneses-Lorente
Johan R de Jong
Keelara Abiraj
P2860
P304
P356
10.1158/1078-0432.CCR-17-0311
P407
P577
2017-07-21T00:00:00Z